CA2987290C - Modified nk-92 cells for treating cancer - Google Patents

Modified nk-92 cells for treating cancer Download PDF

Info

Publication number
CA2987290C
CA2987290C CA2987290A CA2987290A CA2987290C CA 2987290 C CA2987290 C CA 2987290C CA 2987290 A CA2987290 A CA 2987290A CA 2987290 A CA2987290 A CA 2987290A CA 2987290 C CA2987290 C CA 2987290C
Authority
CA
Canada
Prior art keywords
cells
monoclonal antibody
cell
seq
cell line
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2987290A
Other languages
English (en)
French (fr)
Other versions
CA2987290A1 (en
Inventor
Tien Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunitybio Inc
Original Assignee
NantKwest Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NantKwest Inc filed Critical NantKwest Inc
Publication of CA2987290A1 publication Critical patent/CA2987290A1/en
Application granted granted Critical
Publication of CA2987290C publication Critical patent/CA2987290C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/35—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4261—Proteoglycans, e.g. glypican, brevican or CSPG4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/13—Antibody-based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/28—Expressing multiple CARs, TCRs or antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2987290A 2015-06-10 2016-06-10 Modified nk-92 cells for treating cancer Active CA2987290C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562173701P 2015-06-10 2015-06-10
US62/173,701 2015-06-10
US201662337044P 2016-05-16 2016-05-16
US62/337,044 2016-05-16
PCT/US2016/036991 WO2016201304A1 (en) 2015-06-10 2016-06-10 Modified nk-92 cells for treating cancer

Publications (2)

Publication Number Publication Date
CA2987290A1 CA2987290A1 (en) 2016-12-15
CA2987290C true CA2987290C (en) 2023-10-03

Family

ID=57504144

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2987290A Active CA2987290C (en) 2015-06-10 2016-06-10 Modified nk-92 cells for treating cancer

Country Status (10)

Country Link
US (3) US10738279B2 (https=)
EP (3) EP4424326A3 (https=)
JP (4) JP2018517415A (https=)
KR (4) KR20250027585A (https=)
CN (2) CN113502270B (https=)
AU (1) AU2016275030B2 (https=)
CA (1) CA2987290C (https=)
ES (1) ES2958720T3 (https=)
IL (2) IL255884B2 (https=)
WO (1) WO2016201304A1 (https=)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2945320A1 (en) 2014-04-10 2015-10-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Drug regulated transgene expression
AU2015259877B2 (en) 2014-05-15 2021-02-25 National University Of Singapore Modified natural killer cells and uses thereof
EP4424326A3 (en) 2015-06-10 2024-11-13 ImmunityBio, Inc. Modified nk-92 cells for treating cancer
WO2017027291A1 (en) 2015-08-07 2017-02-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Bispecific car t-cells for solid tumor targeting
SG11201810640RA (en) * 2016-06-08 2018-12-28 Intrexon Corp Cd33 specific chimeric antigen receptors
KR102528384B1 (ko) * 2017-01-06 2023-05-02 이뮤너티바이오, 인크. 감소된 cd96/tigit 발현을 갖는 유전자 변형된 nk-92 세포
KR20190102259A (ko) * 2017-01-10 2019-09-03 인트렉손 코포레이션 신규의 유전자 스위치 발현 시스템을 통한 폴리펩티드의 발현 조절
CA3051866A1 (en) * 2017-02-01 2018-08-09 Nant Holdings Ip, Llc Calreticulin-mediated cancer treatment
CA3054078A1 (en) * 2017-02-20 2018-08-23 Dragonfly Therapeutics, Inc. Proteins binding cd33, nkg2d and cd16
KR102769529B1 (ko) 2017-03-08 2025-02-19 이뮤너티바이오, 인크. 임상용 변형된 NK-92 haNK003 세포
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
KR102660336B1 (ko) 2017-03-27 2024-04-26 내셔널 유니버시티 오브 싱가포르 절단된 nkg2d 키메라 수용체 및 자연 살해 세포 면역요법에서의 그의 용도
MX2019011570A (es) 2017-03-27 2019-11-18 Nat Univ Singapore Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales.
EP3601538A4 (en) * 2017-03-27 2021-03-10 Nantcell, Inc. ANK AND IL-12 COMPOSITIONS AND METHODS
BR112019020909A2 (pt) * 2017-04-05 2020-05-12 Korea Research Institute Of Bioscience And Biotechnology Proteína de fusão ativadora de célula nk, célula nk e composição farmacêutica incluindo a mesma
EP4317422A3 (en) * 2017-04-13 2024-05-01 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
JP2020521452A (ja) 2017-05-24 2020-07-27 パンディオン・セラピューティクス・インコーポレイテッド 標的化免疫寛容
TWI676483B (zh) * 2017-08-06 2019-11-11 強普生技股份有限公司 醫藥套組及其用途
EP3697438A4 (en) 2017-10-18 2021-08-18 Intrexon Corporation POLYPEPTIDE COMPOSITIONS WITH SPACERS
US12053490B2 (en) 2017-10-26 2024-08-06 St. Jude Children's Research Hospital, Inc. Methods and compositions for treating CD33+ cancers and improving in vivo persistence of chimeric antigen receptor T cells
WO2019089813A1 (en) * 2017-11-01 2019-05-09 Nantkwest, Inc. Nk-92 cells to stimulate anti-cancer vaccine
CN111788301A (zh) * 2017-11-24 2020-10-16 昂克治疗有限公司 靶向肿瘤细胞的经修饰的自然杀伤细胞和自然杀伤细胞系
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
WO2019127215A1 (en) * 2017-12-28 2019-07-04 Nanjing Legend Biotech Co., Ltd. Multispecific chimeric receptors comprising an nkg2d domain and methods of use thereof
CN110028589B (zh) * 2018-02-07 2023-07-21 阿思科力(苏州)生物科技有限公司 嵌合抗原受体、表达该嵌合抗原受体的nkg2d car-nk细胞及其制备方法和应用
AU2019219454A1 (en) 2018-02-09 2020-08-27 National University Of Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
CN112004829A (zh) 2018-03-12 2020-11-27 南克维斯特公司 Cd33car修饰的高亲和力nk细胞(t-hank)用于降低髓系衍生的抑制细胞的抑制活性(或降低对nk细胞活性的负面影响)的用途
WO2019182425A1 (ko) * 2018-03-23 2019-09-26 주식회사 에스엘바이젠 신규 키메라 항원 수용체 암호화 유전자가 형질도입된 유전자 변형 nk 세포주 및 그의 용도
CN112055717B (zh) 2018-04-02 2024-04-26 新加坡国立大学 用在免疫细胞中表达的膜结合抗细胞因子非信号传导粘合剂中和人细胞因子
IL321548A (en) 2018-05-22 2025-08-01 Immunitybio Inc Recombinant NK cells expressing a chimeric antigen receptor (CAR) for epsilon-FC and uses thereof
WO2020028656A1 (en) 2018-08-01 2020-02-06 Nantkwest, Inc. A quadricistronic system comprising a homing receptor or a cytokine, and chimeric antigen receptor for genetic modification of immunotherapies
US12498363B2 (en) 2018-08-01 2025-12-16 Immunitybio, Inc. Combined invasion and cytotoxicity assay using chemokine secreting target cells
EP3844186A4 (en) 2018-08-29 2022-08-17 National University of Singapore METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
KR102665280B1 (ko) * 2018-10-31 2024-05-10 난트퀘스트, 인크. Cd19-car 발현 nk 세포에 의한 cd19-양성 림프성 악성종양의 제거
KR20240162586A (ko) 2018-10-31 2024-11-15 난트퀘스트, 인크. Pd-l1 키메라 항원 수용체-발현 nk 세포에 의한 pd-l1-양성 악성종양의 제거
IL316887A (en) * 2018-11-06 2025-01-01 Immunitybio Inc NK-92 cells with chimeric antigen receptor modification
US12109238B2 (en) 2018-11-06 2024-10-08 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells
US12590148B2 (en) 2018-11-26 2026-03-31 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
CN121518401A (zh) * 2018-11-26 2026-02-13 免疫生物公司 具有稳定的Fc受体表达的IL-2依赖性NK-92细胞
AU2020232691B2 (en) 2019-03-05 2023-06-29 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
WO2020205100A1 (en) 2019-03-15 2020-10-08 Nantcell, Inc. Recombinant eril-15 nk cells
WO2020236875A1 (en) 2019-05-20 2020-11-26 Pandion Therapeutics, Inc. Madcam targeted immunotolerance
EP4003376A4 (en) * 2019-07-26 2023-09-06 Nantkwest, Inc. CD16+NK-92 CELLS PRELOADED WITH ANTIBODIES AS AN EFFECTIVE THERAPEUTIC PRODUCT FOR TUMOR LYSIS
CN113574169A (zh) * 2019-08-01 2021-10-29 南克维斯特公司 抗b7-h4嵌合抗原受体修饰的nk-92细胞
KR20210033436A (ko) * 2019-09-18 2021-03-26 주식회사 에스엘바이젠 신규 키메라 항원 수용체 암호화 유전자가 형질도입된 유전자 변형 nk 세포주 및 그의 용도
US20210106619A1 (en) * 2019-10-10 2021-04-15 Nantkwest, Inc. NK-92 Bone and Brain targeting
EP4061385A4 (en) * 2019-11-19 2024-08-14 Acibadem Mehmet Ali Aydinlar Üniversitesi METHOD FOR REDESIGNING AND EXPANDING NK92 CELLS FOR USE IN IMMUNOTHERAPY
AU2020387167B2 (en) * 2019-11-20 2024-10-24 Immunitybio, Inc. Cell-mediated transient delivery of immune-enhancing molecules into the tumor microenvironment
CN113646435A (zh) * 2019-12-09 2021-11-12 南克维斯特公司 通过非抗生素依赖性阳性选择筛选表达多基因转基因的细胞克隆
EP4097219A4 (en) * 2020-01-28 2023-10-11 ImmunityBio, Inc. Chimeric antigen receptor-modified nk-92 cells targeting egfr super-family receptors
US11230699B2 (en) 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
CN115397973A (zh) * 2020-01-30 2022-11-25 免疫生物公司 表达car的nk细胞消除bcma阳性恶性肿瘤
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
US20230074303A1 (en) * 2020-03-28 2023-03-09 Board Of Regents, The University Of Texas System Cell immunotherapy for the treatment of cancer
CA3184940A1 (en) 2020-07-07 2022-01-13 Jennifer Donglan WU Mic antibodies and binding agents and methods of using the same
IL302335A (en) * 2020-10-26 2023-06-01 Res Inst Nationwide Childrens Hospital NK cells with chimeric antigen receptor (CAR) and uses thereof
US11591381B2 (en) 2020-11-30 2023-02-28 Crispr Therapeutics Ag Gene-edited natural killer cells
WO2022144632A1 (en) 2020-12-30 2022-07-07 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into nk cells
WO2024236557A1 (en) 2023-05-12 2024-11-21 Gilboa Therapeutics LTD Compositions comprising an fc domain for the treatment of medical conditions
WO2025158400A1 (en) * 2024-01-24 2025-07-31 Yale University Compositions and methods of natural killer cell hyperboosts for enhancement of nk cell therapy

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034332B2 (en) 1997-04-30 2011-10-11 Conkwest, Inc. Interleukin-secreting natural killer cell lines and methods of use
AU7267398A (en) 1997-04-30 1998-11-24 Hans Klingemann Natural killer cell lines and methods of use
WO1999024566A1 (en) 1997-11-06 1999-05-20 Roche Diagnostics Gmbh Tumor-specific antigens, methods for their production and their use for immunization and diagnosis
WO2000020460A1 (en) 1998-10-05 2000-04-13 Ludwig Institute For Cancer Research Methods for producing human tumor antigen specific antibodies
US7098008B2 (en) 2000-04-25 2006-08-29 Ic&G Do. Ltd. Selected primers for detection of MAGE or GAGE genes for diagnosis of cancer and methods of use
SE526227C2 (sv) * 2002-05-15 2005-08-02 North China Pharmaceutical Group Metod för rening av rekombinant humant serumalbumin
DE60334453D1 (de) 2002-05-30 2010-11-18 Macrogenics Inc Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
WO2006004518A1 (en) 2004-07-02 2006-01-12 Avaris Ab Method for the genetic activation of cells and uses of said cells
DE602005016683D1 (de) 2004-07-10 2009-10-29 Fox Chase Cancer Ct Genetisch modifizierte, menschliche, natürliche killerzellenlinien:
US8946385B2 (en) * 2007-01-30 2015-02-03 Chugai Seiyaku Kabushiki Kaisha Chimeric Fcγ receptor and method for determination of ADCC activity by using the receptor
EP2161339A1 (en) * 2008-08-29 2010-03-10 F. Hoffmann-La Roche Ag ADCC with modified NK92 cells
WO2011163401A2 (en) 2010-06-22 2011-12-29 Neogenix Oncology, Inc. Colon and pancreas cancer specific antigens and antibodies
ES2754394T3 (es) 2010-09-08 2020-04-17 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Receptores de antígenos quiméricos con una región bisagra optimizada
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2013051718A1 (ja) 2011-10-07 2013-04-11 国立大学法人三重大学 キメラ抗原受容体
WO2013059593A1 (en) 2011-10-20 2013-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd22 chimeric antigen receptors
CN103483452B (zh) * 2012-06-12 2021-08-13 上海细胞治疗集团有限公司 双信号独立的嵌合抗原受体及其用途
CN104769103B (zh) 2012-09-04 2018-06-08 塞勒克提斯公司 多链嵌合抗原受体和其用途
AU2013327136A1 (en) * 2012-10-02 2015-04-16 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
WO2014099671A1 (en) 2012-12-20 2014-06-26 Bluebird Bio, Inc. Chimeric antigen receptors and immune cells targeting b cell malignancies
EP3447072A3 (en) * 2013-03-05 2019-05-22 Baylor College of Medicine Engager cells comprising cd3 scfv and an antigen recognition domain that binds a tumor antigen for immunotherapy
EP2970426B1 (en) * 2013-03-15 2019-08-28 Michael C. Milone Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
CN115028735A (zh) * 2013-05-03 2022-09-09 俄亥俄州创新基金会 Cs1-特异性嵌合抗原受体工程化的免疫效应细胞
CN104561069A (zh) * 2013-10-23 2015-04-29 深圳先进技术研究院 含重组嵌合抗原受体基因表达盒的微环dna重组母质粒、含该表达盒的微环dna及应用
EP4134085B1 (en) * 2013-11-01 2026-04-29 ImmunityBio, Inc. Tumoricidal and antimicrobial compositions and methods
US20160296562A1 (en) * 2013-11-21 2016-10-13 Ucl Business Plc Cell
EP4424326A3 (en) 2015-06-10 2024-11-13 ImmunityBio, Inc. Modified nk-92 cells for treating cancer
KR102665280B1 (ko) * 2018-10-31 2024-05-10 난트퀘스트, 인크. Cd19-car 발현 nk 세포에 의한 cd19-양성 림프성 악성종양의 제거

Also Published As

Publication number Publication date
WO2016201304A1 (en) 2016-12-15
KR102627811B1 (ko) 2024-01-24
EP3307876A1 (en) 2018-04-18
JP2025089426A (ja) 2025-06-12
IL309167A (en) 2024-02-01
CN113502270B (zh) 2024-06-18
JP2023054220A (ja) 2023-04-13
ES2958720T3 (es) 2024-02-13
CN113502270A (zh) 2021-10-15
US20180163176A1 (en) 2018-06-14
EP4272757A3 (en) 2023-12-27
EP4272757A2 (en) 2023-11-08
KR20230062879A (ko) 2023-05-09
EP4424326A3 (en) 2024-11-13
KR20240013282A (ko) 2024-01-30
US10738279B2 (en) 2020-08-11
CN107709552A (zh) 2018-02-16
CA2987290A1 (en) 2016-12-15
JP2021097694A (ja) 2021-07-01
US20240002802A1 (en) 2024-01-04
KR102526538B1 (ko) 2023-04-28
IL255884B2 (en) 2024-05-01
EP3307876A4 (en) 2019-04-03
IL255884B1 (en) 2024-01-01
KR20180008862A (ko) 2018-01-24
AU2016275030B2 (en) 2021-12-09
US20210054337A1 (en) 2021-02-25
AU2016275030A1 (en) 2017-12-14
JP7275178B2 (ja) 2023-05-17
CN107709552B (zh) 2022-05-13
JP2018517415A (ja) 2018-07-05
EP4424326A2 (en) 2024-09-04
KR20250027585A (ko) 2025-02-26
JP7836780B2 (ja) 2026-03-27
US11788059B2 (en) 2023-10-17
EP3307876B1 (en) 2023-09-13
IL255884A (en) 2018-01-31

Similar Documents

Publication Publication Date Title
US20240002802A1 (en) Modified nk-92 cells for treating cancer
US12473347B2 (en) Elimination of PD-L1-positive malignancies by PD-L1 chimeric antigen receptor-expressing NK cells
US12378300B2 (en) Elimination of CD19-positive lymphoid malignancies by CD19-car expressing NK cells
CA3117936A1 (en) Il-2 dependent nk-92 cells with stable fc receptor expression
HK1251016B (en) Modified nk-92 cells for treating cancer
HK1251016A1 (en) Modified nk-92 cells for treating cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210506

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250603

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250603